| Title |
Endocrine treatment of aging transgender people
|
|---|---|
| Published in |
Reviews in Endocrine and Metabolic Disorders, June 2018
|
| DOI | 10.1007/s11154-018-9449-0 |
| Pubmed ID | |
| Authors |
Louis J. Gooren, Guy T’Sjoen |
| Abstract |
High quality empirical data assessing morbidity and mortality and cancer incidence among transgender people are almost non-existent. Sex hormone treatment of conditions in older non-transgender people might as yet be taken as the best available analogy to hormone administration to aging transgender persons. Testosterone administration to transgender men carries little risk with regard to cardiovascular disease and cancer. A dose adaptation may be needed in men with a high hematocrit or cardiac insufficiency. In transgender men, even after breast ablation, breast cancer may occur in residual mammary tissue. Treatment with estrogens (specifically oral ethinylestradiol) of transgender women, particularly in combination with progestins, carries a significant relative risk of developing cardiovascular disease (almost a twofold incidence compared to the general population). The dose of estrogens may have to be reduced with aging. A change from oral to probably safer transdermal estrogens must be considered. Though rare, tumors of the breasts, prostate, meninges and pituitary have been encountered. Based upon the available expertise, initiation of cross-sex hormone treatment in elderly subjects is without disproportionate risks. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 78 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 14% |
| Researcher | 10 | 13% |
| Student > Postgraduate | 6 | 8% |
| Student > Bachelor | 6 | 8% |
| Student > Doctoral Student | 5 | 6% |
| Other | 16 | 21% |
| Unknown | 24 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 40% |
| Nursing and Health Professions | 6 | 8% |
| Psychology | 4 | 5% |
| Unspecified | 3 | 4% |
| Immunology and Microbiology | 2 | 3% |
| Other | 7 | 9% |
| Unknown | 25 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2018.
All research outputs
#20,456,168
of 25,139,853 outputs
Outputs from Reviews in Endocrine and Metabolic Disorders
#459
of 542 outputs
Outputs of similar age
#260,455
of 334,563 outputs
Outputs of similar age from Reviews in Endocrine and Metabolic Disorders
#5
of 6 outputs
Altmetric has tracked 25,139,853 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 542 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,563 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.